GOLDFISCHER CARL

CIK 00011107806 companiesSAN FRANCISCO, CA

SEC Profile

Transactions

Companies

Filings

CIK

0001110780

Recent Transactions

50 trades

Award
Galecto, Inc.$GLTO
Stock Option (right to buy)
2024-06-20+36,000→ 36,000 total
Award
Galecto, Inc.$GLTO
Stock Option (right to buy)
2023-06-14+36,000→ 36,000 total
Disposition to Issuer
Epizyme, Inc.
Common Stock, par value $0.0001
2022-08-12−3,380,951→ 0 total
Disposition to Issuer
Epizyme, Inc.
Common Stock, par value $0.0001
2022-08-12−8,994→ 0 total
Disposition to Issuer
Epizyme, Inc.
Common Stock, par value $0.0001
2022-08-12−13,060→ 8,994 total
Award
Galecto, Inc.$GLTO
Stock Option (right to buy)
2022-06-14+36,000→ 36,000 total
Award
Enliven Therapeutics, Inc.$ELVN
Stock Options (Right to Buy)
2022-06-02+8,500→ 8,500 total
Award
Epizyme, Inc.
Common Stock, par value $0.0001
2022-05-17+8,994→ 22,054 total
Award
Epizyme, Inc.
Stock Option (Right to Buy)
2022-05-17+41,006→ 41,006 total
Award
Galecto, Inc.$GLTO
Stock Option (right to buy)
2021-11-17+18,000→ 18,000 total
Award
Enliven Therapeutics, Inc.$ELVN
Stock Options (Right to Buy)
2021-06-29+7,728→ 7,728 total
Award
Epizyme, Inc.
Common Stock, par value $0.0001
2021-06-11+8,060→ 13,060 total
Award
Epizyme, Inc.
Stock Option (Right to Buy)
2021-06-11+40,559→ 40,559 total
Award
Galecto, Inc.$GLTO
Stock Option (right to buy)
2021-05-26+18,000→ 18,000 total
Purchase
Epizyme, Inc.
Common Stock, par value $0.0001
2020-11-11$12.07/sh+5,000→ 5,000 total
Conversion
Galecto, Inc.$GLTO
Common Stock
2020-11-02+1,020,036→ 1,020,036 total
Conversion
Galecto, Inc.$GLTO
Series C-3 Preferred Stock
2020-11-02−7,475→ 0 total
Conversion
Galecto, Inc.$GLTO
Series C-3 Preferred Stock
2020-11-02−392,367→ 0 total
Conversion
Galecto, Inc.$GLTO
Common Stock
2020-11-02+19,432→ 19,432 total
Conversion
Galecto, Inc.$GLTO
Common Stock
2020-11-02+9,587→ 9,587 total
Conversion
Galecto, Inc.$GLTO
Series D Preferred Stock
2020-11-02−3,688→ 0 total
Award
Galecto, Inc.$GLTO
Series D Preferred Stock
2020-09-25$27.11/sh+3,688→ 3,688 total
Award
Epizyme, Inc.
Stock Option (Right to Buy)
2020-05-29+14,013→ 14,013 total
Conversion
Enliven Therapeutics, Inc.$ELVN
Series Seed Preferred Stock
2020-03-16−281,878→ 0 total
Conversion
Enliven Therapeutics, Inc.$ELVN
Series B Preferred Stock
2020-03-16−845,008→ 0 total
Conversion
Enliven Therapeutics, Inc.$ELVN
Common Stock
2020-03-16+690,232→ 690,232 total
Conversion
Enliven Therapeutics, Inc.$ELVN
Common Stock
2020-03-16+13,148→ 703,380 total
Conversion
Enliven Therapeutics, Inc.$ELVN
Series B Preferred Stock
2020-03-16−16,103→ 0 total
Conversion
Enliven Therapeutics, Inc.$ELVN
Series A Preferred Stock
2020-03-16−61,378→ 0 total
Conversion
Enliven Therapeutics, Inc.$ELVN
Series A Preferred Stock
2020-03-16−3,220,915→ 0 total
Conversion
Enliven Therapeutics, Inc.$ELVN
Series Seed Preferred Stock
2020-03-16−5,372→ 0 total
Award
Enliven Therapeutics, Inc.$ELVN
Stock Option (right to buy)
2020-03-16+15,457→ 15,457 total
Award
Epizyme, Inc.
Stock Option (Right to Buy)
2019-05-31+17,633→ 17,633 total
Exercise/Conversion
CymaBay Therapeutics, Inc.
Common Stock
2019-02-07$5.00/sh+2,335→ 2,335 total
Exercise/Conversion
CymaBay Therapeutics, Inc.
Common Stock
2019-02-07$5.50/sh+9,340→ 11,675 total
Exercise/Conversion
CymaBay Therapeutics, Inc.
Stock Option (right to buy)
2019-02-07−9,340→ 0 total
Exercise/Conversion
CymaBay Therapeutics, Inc.
Stock Option (right to buy)
2019-02-07−2,335→ 0 total
Sale
CymaBay Therapeutics, Inc.
Common Stock
2019-02-07$9.02/sh−11,675→ 0 total
Award
CymaBay Therapeutics, Inc.
Stock Option (right to buy)
2019-01-29+27,705→ 27,705 total
Award
Epizyme, Inc.
Stock Option (Right to Buy)
2018-05-18+12,500→ 12,500 total
Exercise/Conversion
CymaBay Therapeutics, Inc.
Common Stock
2018-03-22$5.50/sh+5,660→ 15,000 total
Exercise/Conversion
CymaBay Therapeutics, Inc.
Stock Option (right to buy)
2018-03-22−5,660→ 9,340 total
Exercise/Conversion
CymaBay Therapeutics, Inc.
Stock Option (right to buy)
2018-03-22−2,870→ 0 total
Exercise/Conversion
CymaBay Therapeutics, Inc.
Stock Option (right to buy)
2018-03-22−6,470→ 0 total
Exercise/Conversion
CymaBay Therapeutics, Inc.
Common Stock
2018-03-22$5.00/sh+9,340→ 9,340 total
Sale
CymaBay Therapeutics, Inc.
Common Stock
2018-03-22$13.03/sh−15,000→ 0 total
Award
CymaBay Therapeutics, Inc.
Stock Option (right to buy)
2018-01-24+16,000→ 16,000 total
Exercise/Conversion
CymaBay Therapeutics, Inc.
Common Stock
2017-11-02$1.72/sh+9,000→ 9,000 total
Exercise/Conversion
CymaBay Therapeutics, Inc.
Common Stock
2017-11-02$2.97/sh+9,000→ 18,000 total
Sale
CymaBay Therapeutics, Inc.
Common Stock
2017-11-02$8.66/sh−18,000→ 0 total

Companies

Recent Filings

Address

C/O BAY CITY CAPITAL LLC 750 BATTERY STREET, SUITE 400

SAN FRANCISCO, CA, 94111

View on SEC.gov